A prospective study of association of cancer stem cell marker aldehyde dehydrogenase 1 with clinicopathological profile in lung carcinoma patients

Tiwari, Neema; Srivastava, Anand; Tandon, Nishi; Lal, Nirupma; Yadav, Shailendra Kumar; Kant, Surya; Jain, Manoj

doi:10.4103/ijpm.ijpm_318_17

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that the higher the level of ALDH1A1, the worse the prognosis for patients, especially for tumors of the digestive system. Furthermore, ALDH1 is not only involved in many critical biological functions such as cell differentiation and resistance to radiation therapy and chemotherapy but also clinical research found that high expression of the ALDH1 gene signature in cancer tissue is positively correlated with malignant progression in cancer patients ( 14 ). Therefore, it should be clear whether ALDH1 can be used as a therapeutic target for various solid tumor stem cells?…”

Section: Introductionmentioning

confidence: 99%

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors

Wei

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Solid tumors can be divided into benign solid tumors and solid malignant tumors in the academic community, among which malignant solid tumors are called cancers. Cancer is the second leading cause of death in the world, and the global incidence of cancer is increasing yearly New cancer patients in China are always the first. After the concept of stem cells was introduced in the tumor community, the CSC markers represented by ALDH1 have been widely studied due to their strong CSC cell characteristics and potential to be the driving force of tumor metastasis. In the research results in the past five years, it has been found that ALDH1 is highly expressed in various solid cancers such as breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, cervical cancer, esophageal cancer, ovarian cancer, head,and neck cancer. ALDH1 can activate and transform various pathways (such as the USP28/MYC signaling pathway, ALDH1A1/HIF-1α/VEGF axis, wnt/β-catenin signaling pathway), as well as change the intracellular pH value to promote formation and maintenance, resulting in drug resistance in tumors. By targeting and inhibiting ALDH1 in tumor stem cells, it can enhance the sensitivity of drugs and inhibit the proliferation, differentiation, and metastasis of solid tumor stem cells to some extent. This review discusses the relationship and pathway of ALDH1 with various solid tumors. It proposes that ALDH1 may serve as a diagnosis and therapeutic target for CSC, providing new insights and new strategies for reliable tumor treatment.

show abstract

Section: Introductionmentioning

confidence: 99%